Kaiyan Su
YOU?
Author Swipe
View article: Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP
Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP Open
Background: To evaluate the efficacy and safety of two combination treatments for hepatocellular carcinoma (HCC): 1) transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) combined with molecular targeted…
View article: Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial
Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial Open
Introduction: Combining systemic agents with hepatic arterial infusion chemotherapy (HAIC) has produced promising outcomes in advanced hepatocellular carcinoma (HCC). Raltitrexed, an antimetabolite recognized for its extended plasma half-l…
View article: Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis
Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis Open
Our study provides the most comprehensive ABC regulatory maps of the liver to date. This resource offers a valuable reference for identifying regulatory variants and prioritizing susceptibility genes of liver diseases, such as NAFLD.
View article: Bilirubin Targeting WNK1 to Alleviate NLRP3‐Mediated Neuroinflammation
Bilirubin Targeting WNK1 to Alleviate NLRP3‐Mediated Neuroinflammation Open
Bilirubin, an endogenous metabolite with many significant physiological roles, particularly anti‐inflammatory properties, shows great promise as a treatment for inflammatory diseases. However, the binding targets and downstream signaling m…
View article: Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma Open
Background and Aims The impact of low‐level viremia(LLV) on the efficacy of immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma(uHCC) patients remains unclear. This study aims to investigate the effect of LLV on th…
View article: Small molecule activates citrullination through targeting PAD2
Small molecule activates citrullination through targeting PAD2 Open
Citrullination is a post-translational modification catalysed by peptidyl arginine deiminase (PAD) enzymes, and dysregulation of protein citrullination is involved in various pathological disorders. During the past decade, a panel of citru…
View article: Table S1. Compounds mixtures (ten-in-one) information. from Small molecule activates citrullination through targeting PAD2
Table S1. Compounds mixtures (ten-in-one) information. from Small molecule activates citrullination through targeting PAD2 Open
Citrullination is a post-translational modification catalysed by peptidyl arginine deiminase (PAD) enzymes, dysregulation of protein citrullination is involved in various pathological disorders. During the last decade, a panel of citrullin…
View article: Small Molecule Palmatine Targeting Musashi-2 in Colorectal Cancer
Small Molecule Palmatine Targeting Musashi-2 in Colorectal Cancer Open
Musashi-2 (MSI2) is an evolutionally conserved RNA-binding protein and recently considered as an attractive therapeutic target in a wide spectrum of malignancies. However, MSI2-engaged mRNAs are not well profiled, and no MSI2-dependent ant…